Cargando…
Immune Modulatory Cell Therapy for Hemophilia B Based on CD20-Targeted Lentiviral Gene Transfer to Primary B Cells
Gene-modified B cells expressing immunoglobulin G (IgG) fusion proteins have been shown to induce tolerance in several autoimmune and other disease models. However, lack of a vector suitable for gene transfer to human B cells has been an obstacle for translation of this approach. To overcome this hu...
Autores principales: | Wang, Xiaomei, Herzog, Roland W., Byrne, Barry J., Kumar, Sandeep R.P., Zhou, Qi, Buchholz, Christian J., Biswas, Moanaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415320/ https://www.ncbi.nlm.nih.gov/pubmed/28480307 http://dx.doi.org/10.1016/j.omtm.2017.03.005 |
Ejemplares similares
-
Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
por: Sherman, Alexandra, et al.
Publicado: (2017) -
Reprogrammed CD4(+) T Cells That Express FoxP3(+) Control Inhibitory Antibody Formation in Hemophilia A Mice
por: Herzog, Roland W., et al.
Publicado: (2019) -
B cell–activating factor modulates the factor VIII immune response in hemophilia A
por: Doshi, Bhavya S., et al.
Publicado: (2021) -
Clinical development of gene therapy: results and lessons from recent successes
por: Kumar, Sandeep RP, et al.
Publicado: (2016) -
Gene Therapy With Regulatory T Cells: A Beneficial Alliance
por: Biswas, Moanaro, et al.
Publicado: (2018)